If you snore loudly, have observed sleep apneas, or experience daytime sleepiness so severe you nod off while driving, undergo sleep monitoring for obstructive sleep apnea; use nocturnal CPAP for moderate-to-severe disease

Obstructive sleep apnea (OSA) causes repeated airway collapse during sleep, resulting in oxygen drops, frequent micro-arousals, and severe daytime somnolence. Adhering to nocturnal CPAP therapy markedly alleviates daytime sleepiness and reduces motor vehicle crash risk by roughly 70%. However, randomized trials have not demonstrated that CPAP lowers cardiovascular mortality or prolongs lifespan; the primary objective of treatment is restoring daytime alertness and daytime cognitive function.

Involves consultation at a sleep center, pulmonology, or ENT clinic. Diagnostic polysomnography (overnight sleep study) is conducted in-hospital or via home sleep apnea testing devices. For moderate-to-severe disease requiring continuous positive airway pressure (CPAP), purchasing a medical CPAP machine represents a significant out-of-pocket expense ($400–$1,200). The primary hurdle is behavioral persistence: wearing a nasal or oronasal mask nightly takes weeks to adapt, and many patients discontinue use after a few hours per night.

The American Academy of Sleep Medicine (AASM) 2017 diagnostic guidelines identify high pretest probability for moderate-to-severe OSA when persistent daytime sleepiness occurs alongside at least two of the following: loud habitual snoring, witnessed breath-holding or choking during sleep, or diagnosed hypertension. Formal diagnosis requires objective overnight monitoring (polysomnography or home testing), not subjective questionnaires alone. An apnea-hypopnea index (AHI) >=5 events per hour with symptoms, or AHI >=15 events per hour regardless of symptoms, establishes diagnosis. An AASM systematic review and meta-analysis of 38 randomized controlled trials found CPAP reduced Epworth Sleepiness Scale (ESS) scores by 2.4 points (95% CI 1.9–2.8) compared to sham/control. In minimally sleepy patients across 5 trials, ESS reduction was only 1.0 point, deemed clinically insignificant by authors. The same review pooled 10 pre-post intervention studies: CPAP reduced motor vehicle crash rates to 0.3 times baseline (RR 0.3, 95% CI 0.2–0.4), an approximate 70% reduction in crashes. A 2010 meta-analysis of 9 studies found an identical crash risk reduction (RR 0.28, 95% CI 0.22–0.35), noting daytime vigilance improved within one night and driving simulator performance improved within 2 to 7 days. Untreated OSA patients had 1.21 to 4.89 times the crash risk of healthy drivers. Regarding cardiovascular and mortality outcomes, the landmark SAVE randomized controlled trial tracked 2,717 patients aged 45–75 with moderate-to-severe OSA and established cardiovascular disease for a mean 3.7 years: composite cardiovascular events occurred in 17.0% of CPAP patients versus 15.4% of usual care patients, showing no significant difference (HR 1.10, 95% CI 0.91–1.32). Mean CPAP adherence was 3.3 hours per night; CPAP significantly improved snoring, daytime sleepiness, mood, and quality of life. A 2017 JAMA meta-analysis pooling 10 randomized trials (7,266 participants) similarly found CPAP had no statistically significant effect on all-cause mortality (RR 1.13, 95% CI 0.99–1.29) or major cardiovascular events. A 2019 global Lancet study estimated ~176 million Chinese adults aged 30–69 have OSA (23.6% prevalence), with ~65.5 million having moderate-to-severe OSA (8.8% prevalence), the highest absolute volume globally.

Controverted regarding cardiovascular mortality prevention. Randomized trials conclusively demonstrate that CPAP does not reduce hard cardiovascular endpoints or extend lifespan; SAVE participants were minimally sleepy at baseline and achieved average nightly use of 3.3 hours, but stratified meta-analyses by hours of use also showed no difference. Crash risk reductions come from pre-post observational cohorts rather than randomized trials, where treated drivers may have practiced greater caution. The USPSTF (2022) found insufficient evidence to recommend screening asymptomatic adults. Therefore, individuals without snoring or daytime sleepiness do not need screening. Benefit magnitude is categorized as Moderate: ESS reductions reflect meaningful alertness improvements, and crash prevention confers major safety value. If feeling fatigued while driving, pull over immediately (Chapter 1, Rule 9). Excessive daytime napping warrants evaluation (Chapter 2, Rule 37). Managing chronic insomnia is covered in Chapter 3, Rule 26. Primary beneficiaries are yourself, vehicle passengers, and fellow road users.

Kapur VK, Auckley DH, Chowdhuri S, 等 (2017). Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 13(3):479-504. https://doi.org/10.5664/jcsm.6506；Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG (2019). Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. Journal of Clinical Sleep Medicine, 15(2):301-334. https://doi.org/10.5664/jcsm.7638；Tregear S, Reston J, Schoelles K, Phillips B (2010). Continuous positive airway pressure reduces risk of motor vehicle crash among drivers with obstructive sleep apnea: systematic review and meta-analysis. Sleep, 33(10):1373-1380. https://doi.org/10.1093/sleep/33.10.1373；Tregear S, Reston J, Schoelles K, Phillips B (2009). Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. Journal of Clinical Sleep Medicine, 5(6):573-581. https://pubmed.ncbi.nlm.nih.gov/20465027/；McEvoy RD, Antic NA, Heeley E, 等 (2016). CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. New England Journal of Medicine, 375(10):919-931. https://doi.org/10.1056/NEJMoa1606599；Yu J, Zhou Z, McEvoy RD, 等 (2017). Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA, 318(2):156-166. https://doi.org/10.1001/jama.2017.7967；Benjafield AV, Ayas NT, Eastwood PR, 等 (2019). Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. The Lancet Respiratory Medicine, 7(8):687-698. https://doi.org/10.1016/S2213-2600(19)30198-5；US Preventive Services Task Force (2022). Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 328(19):1945-1950. https://doi.org/10.1001/jama.2022.20304